CClinicalTrials.gg
CompletedNCT02947230Updated Feb 21, 2020

Evaluating the Impact of the McMaster Optimal Aging Portal on Physical Mobility Outcomes

An interventional study of Tailored Knowledge Translation in Mobility Limitation, sponsored by McMaster University. Completed at 1 site in Canada. Open to participants aged 40 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-02-21.

Sponsored by McMaster University · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
535
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Study summary

The McMaster Optimal Aging Portal (the Portal) was launched in 2014 to increase public access to trustworthy health information. The Portal helps readers to access evidence-based resources; identify trustworthy messages; and understand scientific findings. Now the investigators want to know whether using the Portal changes what people know and do to stay healthy and mobile.

This project will help us to:

  1. Understand how middle aged and older adults (age 40+) use the Portal to obtain information about maintaining and improving mobility
  2. Evaluate whether use of the Portal results in a change in knowledge about maintaining and improving mobility, or change in lifestyle behaviours that may help maintain or improve mobility with age.
Read the detailed description

Physically active lifestyles are important for health aging, but most Canadians do not meet published physical activity guidelines. This may be in part due to lack of access to evidence-based information on mobility and aging, and knowledge of strategies to maintain or improve mobility with age. The McMaster Optimal Aging Portal (the Portal) was launched in 2014 to increase public access to trustworthy health information. Now the investigators want to know if easy-to-understand evidence-based messages change what people know and do to stay healthy and mobile.

Sequential, explanatory mixed-methods design consisting of a two-armed randomized controlled trial and a qualitative process study to explore quantitative findings in depth.

Consent forms and a baseline survey will be sent to all interested participants. Following baseline data collection, participants will be stratified by previous Portal use, and randomized to the Knowledge Translation (KT) intervention or control group. During the 12-week KT intervention, intervention group participants will have access to the Portal and will receive mobility- focused weekly email alerts including blog posts and evidence summaries relevant to mobility and be invited to follow a Twitter and Facebook feed; a unique hashtag will be created to identify and collate relevant mobility information. Control group participants will be able to access the Portal in a 'self-serve' fashion, but will not receive targeted KT strategies.

02

Conditions studied

  • Mobility Limitation

Browse trials for

Keywords

  • Mobility
  • Aging
  • Knowledge Translation
  • Physical Activity
03

In context

Mobility Limitation

317 studies on the registry are indexed under Mobility Limitation; 97 are open to participants now.

This study's enrollment of 535 is above the median of 46 across 265 interventional studies indexed under Mobility Limitation.

Browse Mobility Limitation studies →

Lead sponsor

McMaster University is the lead sponsor of 720 studies on the registry; 124 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 2 (33%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • English-speaking

Exclusion criteria

Exclusion Criteria:

  • None
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
535 participants (actual)

Study arms

  • Experimental
    Tailored Knowledge Translation

    During the 12-week KT intervention, intervention group participants will have access to the Portal and will receive mobility-focused weekly email alerts including blog posts and evidence summaries relevant to mobility and be invited to follow a Twitter and Facebook feed; a unique hashtag will be created to identify and collate relevant mobility information.

    Other: Tailored Knowledge Translation

  • No intervention
    Control group

    Participants in the control group will have access to the Portal in a 'self-serve' fashion. These participants will be able to browse the Portal, subscribe to email alerts, follow social media, etc. but will not receive the tailored mobility intervention.

Interventions

  • OtherTailored Knowledge Translation

    Tailored knowledge translation strategies specific to maintaining and increasing physical mobility with age.

06

What researchers measure

Primary outcomes

  1. Website analytics

    Understanding participant engagement with the Portal and knowledge translation strategies

    Time frame: 12 weeks

  2. Email analytics

    Understanding participant engagement with the Portal and knowledge translation strategies

    Time frame: 12 weeks

  3. Google analytics

    Understanding participant engagement with the Portal and knowledge translation strategies

    Time frame: 12 weeks

Secondary outcomes

  1. Knowledge Questionnaire

    Participants knowledge of mobility recommendations and guidelines

    Time frame: 12 weeks, 3 months post-intervention

  2. Beliefs Questionnaire

    Participants beliefs about the importance of maintaining and improving mobility for health

    Time frame: 12 weeks, 3 months post-intervention

  3. Intentions Questionnaire

    Participants intentions to engage in lifestyle behaviours related to maintaining or improving mobility

    Time frame: 12 weeks, 3 months post-intervention

  4. Rapid Assessment of Physical Activity

    To quantify self-reported physical activity

    Time frame: 12 weeks, 3 months post-intervention

  5. Manty Preclinical Mobility Disability Scale

    Mobility limitation

    Time frame: 12 weeks, 3 months post-intervention

Other outcomes

  1. Participant satisfaction

    Collected using qualitative interviews

    Time frame: 12 weeks

07

Study locations

1 site
  • McMaster University
    Hamilton, Ontario L8P0A1, Canada
08

References and documents

Publications

  • Neil-Sztramko S, Smith-Turchyn J, Richardson J, Dobbins M. Impact of a Knowledge Translation Intervention on Physical Activity and Mobility in Older Adults (the Move4Age Study): Randomized Controlled Trial. J Med Internet Res. 2020 Feb 11;22(2):e15125. doi: 10.2196/15125. PubMed 32044750 ↗
  • Neil-Sztramko SE, Smith-Turchyn J, Richardson J, Dobbins M. A Mobility-Focused Knowledge Translation Randomized Controlled Trial to Improve Physical Activity: Process Evaluation of the Move4Age Study. J Med Internet Res. 2019 Jun 20;21(6):e13965. doi: 10.2196/13965. PubMed 31223121 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 21, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02947230
Lead sponsor
McMaster University
Responsible party
Sponsor
First posted
Oct 27, 2016
Start date
Mar 7, 2017
Primary completion
Nov 1, 2017
Completion
Dec 31, 2018
Last update
Feb 21, 2020

Study contacts

Maureen Dobbins, RN, PhD
principal investigator · McMaster University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion